Background & Problem
Nuventra’s client requested assistance using modeling and simulation to determine the First-in-Human (FIH) dose for their program. The drug was created to prevent the toxicity of cytotoxic drugs. However, the sponsor felt that the drug could be studied in healthy volunteers in Phase 1, if given carefully and for a short period of time. Conducting a Phase 1 study in healthy volunteers would greatly accelerate clinical development.
That is where Nuventra came in – to help determine how much of the drug could be given and for how long while ensuring subject safety.
Nuventra developed a PK/PD model based entirely on the client’s pre-clinical data. Pre-clinical data used in the model included pharmacokinetics (PK) data and precursor data from mice cell populations when dosed with the drug alone and when dosed with chemotherapy. The mouse data was used to construct a systems pharmacology model that included both the cytotoxic effects of chemotherapy and the protective effects of the drug.
This model was then scaled to humans. Based on the model, Nuventra was able to predict the minimum effective dose in humans and the range of the clinical dose. Importantly, Nuventra also predicted that the drug infusion should occur a specific amount of time prior to cytotoxic therapy to deplete the population of precursor cells.
The FIH study was designed based on these simulations and predictions. When the FIH study data became available, the investigator commented that the predictions for the magnitude and timing of the effects on both precursor cells and peripheral white blood cells as well as the pharmacokinetics were “remarkably accurate.”
The drug program was approved by the FDA. The final drug label includes dosing information in line with predictions made by Nuventra.